Literature DB >> 2430808

Benign prostatic hyperplasia treated by castration or the LH-RH analogue buserelin: a report on 6 cases.

F H Schroeder, M Westerhof, R J Bosch, K H Kurth.   

Abstract

This article presents the clinical data of 5 patients treated by castration and 1 patient treated with an LH-RH analogue to relieve chronic urinary retention due to benign prostatic hyperplasia (BPH). Besides the clinical data related to prostatism, prostatic volume was studied in 4 of the 5 patients by means of transrectal ultrasonography. All 5 patients showed a marked decrease of prostatic volume, which averaged 31.4% (range 19-55%) after 2-3 months. This correlated well with a relief of urinary obstruction. In all 5 patients, the indwelling catheters could be removed, symptoms decreased or disappeared and all 5 patients became free of residual urine. LH-RH analogues, because of the reversibility of their effect, may be more acceptable for the treatment of BPH than castration. At this moment however, it remains unknown whether prostatic volume will increase again after cessation of androgen withdrawal.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2430808     DOI: 10.1159/000472646

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  8 in total

Review 1.  Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses.

Authors:  B J Furr; J R Woodburn
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

Review 2.  Benign prostatic hyperplasia. Practical treatment guidelines.

Authors:  T Tammela
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

3.  Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.

Authors:  Kouji Izumi; Lei Li; Chawnshang Chang
Journal:  Clin Investig (Lond)       Date:  2014-10-01

Review 4.  Regulation of prostate growth by fibroblast growth factors.

Authors:  M T Story
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

Review 5.  Androgen receptor roles in the development of benign prostate hyperplasia.

Authors:  Kouji Izumi; Atsushi Mizokami; Wen-Jye Lin; Kuo-Pao Lai; Chawnshang Chang
Journal:  Am J Pathol       Date:  2013-04-06       Impact factor: 4.307

6.  Pharmacotherapy for benign prostatic hyperplasia.

Authors:  P Narayan; R Indudhara
Journal:  West J Med       Date:  1994-11

Review 7.  Lower urinary tract symptoms in men.

Authors:  John M Hollingsworth; Timothy J Wilt
Journal:  BMJ       Date:  2014-08-14

Review 8.  Medical therapy for benign prostatic hyperplasia progression.

Authors:  Kevin T McVary
Journal:  Curr Urol Rep       Date:  2002-08       Impact factor: 2.862

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.